Table 1.
Selected demographic characteristics for cancers diagnosed between 2005 and 2015
| WTC‐MMTP (n = 2,037) | WTC non‐MMTP (n = 564) | NYS‐non‐responders (n = 574,075) | |
|---|---|---|---|
| Race/ethnicity, n (%) | |||
| Non‐Hispanic White | 1,611 (79.1) | 388 (68.8) | 343,275 (59.8) |
| Non‐Hispanic Black | 213 (10.5) | 91 (16.1) | 104,470 (18.2) |
| Non‐Hispanic Asian/Pacific Islander | 10 (0.5) | 14 (2.5) | 40,025 (7.0) |
| Hispanic | 194 (9.5) | 62 (11.0) | 80,844 (14.1) |
| Non‐Hispanic other | 9 (0.4) | 9 (1.6) | 5,461 (1.0) |
| Sex, n (%) | |||
| Male | 1,870 (91.8) | 431 (76.4) | 285,033 (49.7) |
| Female | 167 (8.2) | 133 (23.6) | 289,042 (50.3) |
| Age at diagnosis, mean (SD) | 55.5 (9.6) | 57.4 (10.0) | 64.1 (14.0) |
| Smoking status, n (%) | |||
| Ever | 885 (43.5) | 302 (53.6) | 0 (0.0) |
| Never | 1,105 (54.3) | 251 (44.5) | 0 (0.0) |
| Unknown | 47 (2.3) | 11 (2.0) | 574,075 (100.0) |
| Year of diagnosis | |||
| 2005–2008 | 457 (22.4) | 204 (36.2) | 206,887 (36.0) |
| 2009–2012 | 825 (40.5) | 188 (33.3) | 209,387 (36.5) |
| 2013–2015 | 755 (37.1) | 172 (30.5) | 157,801 (27.5) |
| Type of primary cancer diagnosis, n (%) | |||
| Prostate | 659 (32.4) | 162 (28.7) | 93,135 (16.2) |
| Melanoma of the skin | 138 (6.8) | 20 (3.5) | 17,436 (3.0) |
| Colon and rectum | 136 (6.7) | 32 (5.7) | 53,767 (9.4) |
| Thyroid | 133 (6.5) | 24 (4.3) | 22,667 (4.0) |
| Lung and bronchus | 110 (5.4) | 42 (7.4) | 58,386 (10.2) |
| Kidney and renal pelvis | 95 (4.7) | 27 (4.8) | 17,756 (3.1) |
| Urinary bladder | 87 (4.3) | 18 (3.2) | 23,459 (4.1) |
| Breast | 58 (2.8) | 54 (9.6) | 85,663 (14.9) |
| Myeloma | 35 (1.7) | 15 (2.7) | 10,183 (1.8) |
| Pancreas | 35 (1.7) | 9 (1.6) | 15,256 (2.7) |
| Brain and other nervous system | 28 (1.4) | 10 (1.8) | 6,327 (1.1) |
| Esophagus | 26 (1.3) | 9 (1.6) | 4,852 (0.9) |
| Liver | 26 (1.3) | 8 (1.4) | 10,588 (1.8) |
| All other sites | 471 (23.1) | 134 (23.8) | 154,600 (26.9) |
| Staging, n (%) | |||
| Localized | 1,200 (58.9) | 324 (57.4) | 270,891 (47.2) |
| Regional | 387 (19.0) | 102 (18.1) | 120,194 (20.9) |
| Distant | 341 (16.7) | 106 (18.8) | 137,277 (23.9) |
| Unknown | 109 (5.4) | 32 (5.7) | 45,713 (8.0) |
| Deaths, n (%) | 303 (14.9) | 143 (25.4) | 224,040 (39.0) |
| Cancer deaths, n (%) | 248 (12.2) | 106 (18.8) | 158,645 (27.6) |
| Survival rate, n (%) | |||
| 1‐year survival a | 1916 (94.1) | 507 (89.9) | 474,895 (82.7) |
| 3‐year survival b | 1346 (88.3) | 372 (81.2) | 326,959 (69.6) |
| 5‐year survival c | 919 (86.1) | 266 (76.0) | 228,933 (62.8) |
| Person–time (year) median (IQR) d | 4.5 (2.3, 7.1) | 4.5 (2.2, 8.0) | 3.7 (1.5, 7.1) |
Abbreviations: IQR, interquartile range; NYS‐non‐responders, all other cancer patients who were residents of the 11‐southernmost counties of New York State and were not included in one of the WTC‐responder cohorts; WTC‐MMTP, cancer patients enrolled in the World Trade Center Medical Monitoring and Treatment Program; WTC‐non‐MMTP, WTC‐exposed cancer patients who were NOT enrolled in the WTC‐MMTP.
Percentages calculated among participants who had an opportunity to accrue at least 1 year of follow‐up.
Percentages calculated among participants who had an opportunity to accrue at least 3 years of follow‐up.
Percentages calculated among participants who had an opportunity to accrue at least 5 years of follow‐up.
Person–time calculated from the time of diagnosis to death or end of follow‐up.